Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Company Deals

Insilico Medicine and THPharma Launch AI Research Collaboration to Build ‘Reverse Translation’ Drug Discovery Strategy Around Phase 3 Candidate THP-001

Fineline Cube Aug 13, 2026
Policy / Regulatory

NMPA Releases Draft Implementation Rules for the National Key R&D Program – Public Comment Open Through 12 Sept 2026

Fineline Cube Aug 14, 2026
Company Drug

Yiling Pharmaceutical Files IND in China for LB220-D08, a First-In-Class Factor B Inhibitor for aHUS

Fineline Cube Aug 17, 2026
Company Drug

Pfizer and Valneva See EMA Validate MAA for PF‑07307405, the First‑Potential Blockbuster Lyme Disease Vaccine

Fineline Cube Aug 17, 2026
Company Drug

Merck’s Keytruda Receives 10th Indication Approval in China for TNBC

Fineline Cube Nov 9, 2022

US-based Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab) has...

Company Deals

Takeda Partners with CCCMHPIE to Boost Rare Disease Drug Access in China

Fineline Cube Nov 8, 2022

The 5th China International Import Expo (CIIE) saw Japan-based Takeda Pharmaceutical Co., Ltd’s China unit...

Company Deals

Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies

Fineline Cube Nov 8, 2022

Xellsmart, a stem-cell startup based in Suzhou, has reportedly raised over RMB 200 million (USD...

Company

Novo Nordisk Reports 16% YOY Growth in Q3, Raises Full-Year Guidance

Fineline Cube Nov 8, 2022

Denmark-based biopharma Novo Nordisk A/S (NYSE: NVO) has released its Q3 2022 earnings report. The...

Company Deals

Novo Nordisk Partners with Shanghai Pharma for Smart Logistics at CIIE

Fineline Cube Nov 8, 2022

Novo Nordisk (NYSE: NVO) has announced a strategic partnership with China’s Shanghai Pharmaceuticals (HKG: 2607,...

Company Deals

SIMR Biotechnology Raises RMB 150M in Series C1 Financing Round

Fineline Cube Nov 8, 2022

China’s Shanghai SIMR Biotechnology Co., Ltd has reportedly raised RMB 150 million (USD 20.7 million)...

Company Deals Digital

PingAn Good Doctor Partners with Roche and OrigiMed at CIIE

Fineline Cube Nov 8, 2022

The 5th China International Import Expo (CIIE) saw China-based Ping An Healthcare and Technology Co.,...

Company Deals Digital

Organon Partners with Alibaba Health to Enhance Chronic Disease Management

Fineline Cube Nov 8, 2022

Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that...

Company Drug

Qilu Pharma’s QL1706 Shows Promise in Phase II Cervical Cancer Study

Fineline Cube Nov 8, 2022

China-based Qilu Pharmaceutical has published the latest results from a Phase II clinical study for...

Company Deals

Organon Sponsors Retail Pharmacy Health Center at CIIE

Fineline Cube Nov 8, 2022

The 5th China International Import Expo (CIIE) saw Organon & Co. (NYSE: OGN), a firm...

Company Deals

Sanofi Partners with China Resources Sanjiu at CIIE for Consumer Healthcare

Fineline Cube Nov 8, 2022

The 5th China International Import Expo (CIIE) saw Sanofi’s consumer healthcare unit announce a partnership...

Company Deals

Sumitomo Dainippon Partners with Profex to Promote Antipsychotics in China

Fineline Cube Nov 8, 2022

Japan-based Sumitomo Dainippon Pharma Co., Ltd has announced a partnership with Profex, a trade company...

Company Deals

Eli Lilly Partners with AmoyDx and Burning Rock for Retevmo Companion Diagnostics

Fineline Cube Nov 7, 2022

The 5th China International Import Expo (CIIE) saw US-based Eli Lilly (NYSE: LLY) announce a...

Company

BioNTech’s Comirnaty Gets Limited Authorization in China Amid Scholz Visit

Fineline Cube Nov 7, 2022

Germany-based mRNA specialist BioNTech (NASDAQ: BNTX) reportedly benefited from German Chancellor Olaf Scholz’s visit to...

Company

Organon’s Q3 Results Show Women’s Health Segment Outperforms Amid Global Revenue Decline

Fineline Cube Nov 7, 2022

US-based Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health...

Company Deals

Organon Signs MOU with China’s National Health Commission at CIIE

Fineline Cube Nov 7, 2022

Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that...

Company Drug

Ascletis Pharma Presents Phase I Study Results for ASC43F at AASLD

Fineline Cube Nov 7, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) made a poster presentation detailing the abstract of a...

Company Drug

Ji Xing Pharmaceuticals’ Omecamtiv Mecarbil Accepted for Review by CDE

Fineline Cube Nov 7, 2022

Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, announced that a market filing for its...

Company Deals

Sophway Raises ‘Tens of Millions’ in Angel Round for Endoscope Development

Fineline Cube Nov 7, 2022

Sophway Technology, a full HD endoscope system developer based in Shenzhen, has reportedly raised “tens...

Company Deals

CIIE: MET HER2 Precision Diagnosis Alliance Formed to Advance Lung Cancer Treatment

Fineline Cube Nov 7, 2022

The 5th China International Import Expo (CIIE) witnessed the establishment of the MET HER2 precision...

Posts pagination

1 … 647 648 649 … 708

Recent updates

  • Yiling Pharmaceutical Files IND in China for LB220-D08, a First-In-Class Factor B Inhibitor for aHUS
  • Pfizer and Valneva See EMA Validate MAA for PF‑07307405, the First‑Potential Blockbuster Lyme Disease Vaccine
  • Sino Medical Sciences Wins Turkish Approval for Ghunter Intracranial Thrombectomy Stent – Broadening Global Footprint in Ischemic Stroke Care
  • Bristol-Myers Squibb Secures FDA Approval for Iberdomide Combination in Multiple Myeloma – First‑Ever Nod Based on MRD‑Negative Response Data
  • Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Yiling Pharmaceutical Files IND in China for LB220-D08, a First-In-Class Factor B Inhibitor for aHUS

Company Drug

Pfizer and Valneva See EMA Validate MAA for PF‑07307405, the First‑Potential Blockbuster Lyme Disease Vaccine

Company Medical Device

Sino Medical Sciences Wins Turkish Approval for Ghunter Intracranial Thrombectomy Stent – Broadening Global Footprint in Ischemic Stroke Care

Company Drug

Bristol-Myers Squibb Secures FDA Approval for Iberdomide Combination in Multiple Myeloma – First‑Ever Nod Based on MRD‑Negative Response Data

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.